第5章 競爭評估

第6章 機會及未滿足需求

第7章 開發平台評估

概要

臨床試驗的測繪

臨床開發中的有潛力疫苗

初期開發階段的創新性人類乳突病毒(HPV)疫苗

第8章 現在/未來的主要企業

概要

企業策略趨勢

企業簡介

Merck

GSK

第9章 市場預測

全球市場

美國

法國

德國

義大利

西班牙

英國

日本

澳洲

加拿大

第10章 附錄

圖表

目錄

Product Code: GDHC84PIDR

The first prophylactic vaccine for immunization against human papillomavirus (HPV) became available in 2006. The global HPV vaccines market is now well established, yet vaccine coverage rates amongst the traditional target population of adolescent girls remain persistently low. Initially HPV vaccines were developed and marketed solely to protect against cervical cancer. In recent years the role of HPV in other cancers has been increasingly recognized which has facilitated a shift towards vaccinating a wider population, most significant has been the inclusion of males in routine vaccine recommendations in some countries. The current HPV vaccines market is dominated by one major player, Merck's Gardasil, with GlaxoSmithKline's (GSK's) HPV vaccine Cervarix providing the only competition. The introduction of Merck's nine-valent vaccine (V503) is set to change the future landscape of the HPV vaccines sector.

Highlights

Key Questions Answered

What environmental factors limit the uptake of current HPV vaccines?

What opportunities exist to overcome these environmental factors?

What are the main unmet needs of current HPV vaccines?

What technologies are positioned to address these unmet needs?

What opportunities will remain for the development of new HPV vaccines?

What environmental factors will influence the introduction of novel HPV vaccines?

Key Findings

New nine-valent HPV vaccines are expected to be widely adopted following market approval, stealing market share from existing vaccines. Though a high price represents a potential barrier to market access.